Poliomyelitis vaccine

A polio and vaccine technology, applied in biochemical equipment and methods, viral antigen components, microorganisms, etc., can solve problems such as the joint action of polioviruses that are not involved, and achieve the enhancement of specific immune responses, reduction of vaccine costs, The effect of reducing the dosage

Inactive Publication Date: 2009-10-21
NAT VACCINE & SERUM INST
View PDF1 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, none of these documents refer to inactivated poliovirus as an antigen alone with an oligodeoxynucleotide containing at least one unmethylated CpG dinucleotide (the length of the oligodeoxynucleotide is 15- 35 nucleotides) combined effect of the first adjuvant

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Poliomyelitis vaccine
  • Poliomyelitis vaccine
  • Poliomyelitis vaccine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] Example 1. Preparation of Inactivated Poliovirus

[0036] Cells: African green monkey kidney passage cell line (Vero cell line) was used. The cells were isolated from the kidney of African green monkeys by Japanese scholars in 1963. The 112th generation was sent to the American Type Culture Collection (ATCC). After identification, the cells had no tumorigenicity, no bacteria, mold and mycoplasma contamination, no virus contamination, and were suitable for the production of biological products.

[0037] In December 1988, the Beijing Institute of Biological Products obtained a second bottle of 117-generation Vero cells (numbered CCL81) from ATCC in the United States, and immediately frozen them in liquid nitrogen as the original seeds. The main cell bank was prepared by subculture and expansion of an original seed, and the working cell bank was prepared by subculture and expansion of a master seed bank cell. The verification of the main cell bank and the working cell ba...

Embodiment 2

[0047] Example 2 CpG-ODN can enhance the immune response of mice to Sabin II type inactivated polio vaccine

[0048] The inactivated poliovirus used in this example was prepared according to the method described in Example 1, and is hereinafter referred to as Ag for short.

[0049] The CpG-ODN used in this example was designed by the inventors, and its sequence is as follows: 5′-TCGTTCGTTCGTTCGTTCGTT-3′, which was artificially synthesized by Shanghai Sangon Biotechnology Co., Ltd., and subjected to full-chain thio modification, and polyacrylamide gel electrophoresis Purified, dissolved in normal saline, and stored in a -20°C refrigerator for later use.

[0050] The mice used in this example are Balb / c mice, female, 6-8 weeks old, purchased from the Experimental Animal Center of the Chinese Academy of Medical Sciences.

[0051] Divide the Balb / c mice into four groups, namely "Ag group", "Ag+Al group", "Ag+CpG group" and "Ag+Al+CpG group", with 8 mice in each group, each The m...

Embodiment 3

[0060] Example 3. CpG-ODN can reduce the antigen dosage of Sabin II type inactivated polio vaccine

[0061] Balb / c mice were immunized according to the same method as in Example 2, and then specific IgG antibody titers and neutralizing antibody titers were detected to determine the antigen dosage of CpG-ODN to Sabin II type inactivated polio vaccine The difference is that the amount of antigen used in inactivated polio vaccine is the original dose (10 μg Ag / mouse), one-quarter dose (2.5 μg Ag / mouse) and one-sixteenth Dose (0.625 μg of Ag / mouse). See the results separately Figure 2a and 2b .

[0062] Figure 2a The results shown are the Sabin II poliovirus-specific IgG antibody titers at the 4th week after immunization. Depend on Figure 2a It can be seen that the "Ag+CpG group" only needs a quarter of the dose of Ag to achieve the immune effect of the original antigen dose of the "Ag group". The "Ag+Al+CpG group" had the strongest immune response, and only one sixteent...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a poliomyelitis vaccine comprising an inactivated poliomyelitis virus used as an antigen, and a first adjuvant, wherein the first adjuvant is oligodeoxynucleotide comprising at least one non-methylation CpG dinucleotide, and the length of the oligodeoxynucleotide is 15-35 ribonucleotides. The adjuvant used for increasing the immunization effect of the inactivated poliomyelitis vaccine is a novel human vaccine adjuvant with favorable potential application prospect, and the chemical essence of the adjuvant is the oligodeoxynucleotide which is synthesized manually and contains the CpG dinucleotide. By a receptor TLR9 activated immune system on immune cells, the adjuvant reinforces specific immune response aiming at vaccine antigens. The immunization effect of a vaccine can be increased by adding the vaccine adjuvant into the vaccine, so that the dosage of the vaccine antigen can be reduced and the vaccine cost can be reduced finally.

Description

technical field [0001] The invention relates to the field of biopharmaceuticals, in particular to a polio vaccine. Background technique [0002] Vaccination against polio is the main way to prevent poliovirus infection. Through the use of oral attenuated polio vaccine, my country has completely eliminated polio caused by wild-type virus, but there are still vaccine-related cases caused by vaccine strain mutation. Inactivated polio vaccine is a trivalent vaccine comprising poliovirus serotypes I, II and III. Since there is no wild strain circulating in my country, only the attenuated Sabin strain with weak immunogenicity can be used to develop inactivated polio vaccine. The immune effect of this inactivated vaccine is poor, the yield is low, and the price is expensive, so it is impossible to use it on a large scale nationwide as a planned immunization vaccine. [0003] At present, all developed countries use inactivated polio vaccines produced from wild strains. Poliomyel...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/39A61K39/12C12N7/00A61P31/14
CPCY02A50/30
Inventor 许洪林杨春亭周军
Owner NAT VACCINE & SERUM INST
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap